Decline in serum androgens and survival in metastatic castration resistant prostate cancer (MCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (alliance)
Publication/Presentation Date
3-2018
Volume
17
Issue
2
First Page
1073
Last Page
1073
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS